MEGF8 Products


Chimera RNA interference (chimera RNAi) is process by which small interfering RNA/DNA chimera triggers the destruction of mRNA for the original gene. The discovery work, design, and application of chimera RNAi has been pioneered by Professor Kaoru Saigo and Dr. Kumiko Ui-Tei at the University of Tokyo. Chimera RNAi has many advantages over the conventional siRNAs. First, it has been demonstrated to have reliable knock-down for over 10,000 human genes. Because the human genome is composed of an intricate, genetic network, chimera RNAi's unique design has successfully obviated the off-target effects including microRNA-based influence. Another advantage of the chimera RNAi technology is its effectiveness at low concentrations (0.5nM to 5nM); only mRNA is destroyed so genomic genes are not affected. Finally, having both the sense and anti-sense strands consisting RNA/DNA chimera, it offers much greater compound stability for streamlining in vitro and in vivo assays and applications while minimizing interferon induction and other adverse reactions.


Entrez Human
Uniprot Human
Product By Gene ID 1954
Alternate Names
  • KIAA0817
  • EGF-like protein 4
  • multiple epidermal growth factor-like domains protein 8
  • C19orf49
  • multiple epidermal growth factor-like domains 8
  • Multiple EGF-like domains protein 8
  • multiple EGF-like domain protein 4
  • Epidermal growth factor-like protein 4
  • HBV pre-s2 binding protein 1
  • EGF-like-domain, multiple 4
  • EGF-like domain-containing protein 4
  • SBP1
  • MGC138147
  • FLJ22365
  • EGFL4MGC120684
  • chromosome 19 open reading frame 49
  • multiple EGF-like-domains 8

Pathways for MEGF8

View related products by pathway and learn more about each of the pathways below.

Cell Death
Chromatin Remodeling

Bioinformatics Tool for MEGF8

Discover related pathways, diseases and genes to MEGF8. Need help? Read the Bioinformatics Tool Guide for instructions on using this tool.
Vizit™, under license from BioVista Inc.